Share

April 07, 2015; 84 (14) Article

Predicting the risk of mild cognitive impairment in the Mayo Clinic Study of Aging

V. Shane Pankratz, Rosebud O. Roberts, Michelle M. Mielke, David S. Knopman, Clifford R. Jack, Yonas E. Geda, Walter A. Rocca, Ronald C. Petersen
First published March 18, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001437
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1401

Share

Article Information

vol. 84 no. 14 1433-1442
DOI: 
https://doi.org/10.1212/WNL.0000000000001437
PubMed: 
25788555
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received March 31, 2014
  • Accepted in final form November 20, 2014
  • First Published March 18, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. V. Shane Pankratz, PhD,
    2. Rosebud O. Roberts, MBChB,
    3. Michelle M. Mielke, PhD,
    4. David S. Knopman, MD,
    5. Clifford R. Jack Jr, MD,
    6. Yonas E. Geda, MD,
    7. Walter A. Rocca, MD, MPH and
    8. Ronald C. Petersen, MD, PhD
  1. V. Shane Pankratz, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIA, P50 AG16574, Data Core Director, 2004-present (2) NIA, U01 AG06786, Co-Investigator, 2005-present (3) NIA, R01 AG32990, Co-Investigator, 2009-present

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Rosebud O. Roberts, MBChB,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Journal of Alzheimer's Disease; Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH U01 AG006786 [Coinvestigator] 2009-2014

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Mayo Clinic [coinvestigator], Driskill Foundation, and GHR Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Michelle M. Mielke, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have received speaker honoraria from Eli Lilly and AbbVie.

    Editorial Boards:

    1. Alzheimer's and Dementia: The Journal of the Alzheimer Association, associate editor, 2012-present Journal of Alzheimer Disease, associate editor, 2012-present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Eli Lilly and AbbVie

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr. Mielke was funded by the following NIH grants: U01 AG037526 U01 AG006786

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr. Mielke also received research support from the Walter S. and Lucienne B. Driskill Foundation which started in May 2012-present. Alzheimer drug discovery foundation. Role:PI. Date: 03/01/2013-present Michael J. Fox Foundation. Role: PI. Date: 01/01/2014-06/30/2015.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. David S. Knopman, MD,
    5. Scientific Advisory Boards:

    1. Consultant Bluefield project (frontotemporal demantia); Lundbeck Pharmaceuticals (Sept 2013 ongoing); DIAN study DSMB (Sept 2013 ongoing).

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Lecture, University of Pennsylvania, January 2013 (2) Lecture, St Johns Hospital, Jackson Hole Wyoming June 2013 (3) Lecture, Amer Soc Neuroradiol, San Diego CA, May 2013 (4) Lectures, Alzheimer Conference, Seoul Korea, December 2014

    Editorial Boards:

    1. Neurology, Deputy Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Tau Rx clinical trial

    Research Support, Government Entities:

    1. NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer?s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Clifford R. Jack Jr, MD,
    6. Scientific Advisory Boards:

    1. scientific advisory panels: Janssen and Eli Lily

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health: RO1 AG011378 PI; U01 AG024904-01 co-I; RO1 AG37551 co-I; 1U01HL096917 co-I; U01 AG032438 co-I; RO1 AG041851-01 co- PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. own stock in Johnson and Johnson

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. Johnson and Johnson

    Legal Proceedings:

    1. NONE

  6. Yonas E. Geda, MD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 2013 to present : Member, editorial board of International Psychogeriatrics.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institutes of Health (NIH), K01 MH068531

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. 1-Harold Amos Medical Faculty Development Award (RWJ foundation). 2- European Union Regional Development Fund (CZ.1.05/1.1.00/02.0123)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Walter A. Rocca, MD, MPH and
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. 2008 - to present: Revista de Neurologia (in Spanish) 2008 - to present: Clinical Epidemiology & Risk Management 2008 - to present: Maturitas 2009 - to present: Menopause Dr. Rocca is a member of the editorial boards of the above-listed journals. No compensation is received from any of these journals for his participation.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Dr. Rocca receives research support from the NIH (R01 AG034676 [PI]; U01 AG006786 [coinvestigator]), and from the NIH P50 AG044170[coinvestigator].)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Ronald C. Petersen, MD, PhD
    9. Scientific Advisory Boards:

    1. (1) Pfizer, Inc., Chair, Data Monitoring Committee; (2) Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. Mild Cognitive Impairment,Oxford University Press, 2003

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Roche Incorporated, (2) Merck, (3) Genentech

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) R01-AG011378 (Co-I) U01-AG024904 (Co-I) Non-financial disclosures: National Advisory Council on Aging, National Institute on Aging

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Internal Medicine (V.S.P.), University of New Mexico Health Sciences Center, Albuquerque; Division of Epidemiology, Department of Health Sciences Research (R.O.R., M.M.M., W.A.R., R.C.P.), and Departments of Neurology (R.O.R., M.M.M., D.S.K., R.C.P.) and Radiology (C.R.J.), Mayo Clinic, Rochester, MN; and the Departments of Psychiatry, Psychology, and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.
  1. Correspondence to Dr. Petersen: peter8{at}mayo.edu

Article usage

Article usage: March 2015 to October 2023

AbstractFullPdfSource
Mar 201579460323Highwire
Apr 2015288571165Highwire
May 201510903460Highwire
Jun 20156582436Highwire
Jul 20156121533Highwire
Aug 2015398815Highwire
Sep 20152621716Highwire
Oct 20153771720Highwire
Nov 20152011522Highwire
Dec 2015224511Highwire
Jan 20162741515Highwire
Feb 201625069Highwire
Mar 201624489Highwire
Apr 201623673Highwire
Apr 201602416pmc
May 201618568Highwire
May 201603223pmc
Jun 201613323Highwire
Jun 201601923pmc
Jul 201615685Highwire
Jul 201602211pmc
Aug 201619113Highwire
Aug 201602914pmc
Sep 201614700Highwire
Sep 201602718pmc
Oct 201624966Highwire
Oct 201604618pmc
Nov 201616213Highwire
Nov 20160217pmc
Dec 201615333Highwire
Dec 20160257pmc
Jan 201753123Highwire
Jan 20170216pmc
Feb 201727905Highwire
Feb 201702416pmc
Mar 201716723Highwire
Mar 201703213pmc
Apr 201731521Highwire
Apr 201772529pmc
May 201723632Highwire
May 2017163128pmc
Jun 201719401Highwire
Jun 201771720pmc
Jul 201718729Highwire
Jul 2017102219pmc
Aug 201715312Highwire
Aug 201792729pmc
Sep 201718300Highwire
Sep 201783334pmc
Oct 201719342Highwire
Oct 201711918pmc
Nov 201721432Highwire
Nov 2017163642pmc
Dec 201712952Highwire
Jan 201820513Highwire
Feb 201812541Highwire
Mar 201815930Highwire
Apr 201813852Highwire
Apr 201863236pmc
May 201818164Highwire
Jun 201823522Highwire
Jun 201872527pmc
Jul 201812011Highwire
Aug 201813424Highwire
Aug 201882830pmc
Sep 201810645Highwire
Oct 201815424Highwire
Nov 201820033Highwire
Dec 201814910Highwire
Jan 201914422Highwire
Feb 201911524Highwire
Mar 201911500Highwire
Apr 201911010Highwire
May 20198202Highwire
Jun 20199824Highwire
Jul 20198601Highwire
Aug 20199712Highwire
Sep 20199600Highwire
Oct 201910623Highwire
Nov 201910265Highwire
Dec 20197832Highwire
Jan 20206300Highwire
Feb 20205422Highwire
Mar 20204820Highwire
Apr 20205112Highwire
May 20203001Highwire
Jun 20204811Highwire
Jul 20203100Highwire
Aug 20204000Highwire
Sep 20204613Highwire
Oct 20202410Highwire
Nov 20203621Highwire
Dec 20205501Highwire
Jan 20215111Highwire
Feb 20214702Highwire
Mar 20214132Highwire
Apr 20217310Highwire
May 20218731Highwire
Jun 20215924Highwire
Jul 20214111Highwire
Aug 20213823Highwire
Sep 20219514Highwire
Oct 20215810Highwire
Nov 20215836Highwire
Dec 20215940Highwire
Jan 20224830Highwire
Feb 20226111Highwire
Mar 20226300Highwire
Apr 20227300Highwire
May 20229001Highwire
Jun 20224322Highwire
Jul 20225802Highwire
Aug 20228300Highwire
Sep 20224200Highwire
Oct 202216100Highwire
Nov 20224821Highwire
Dec 20227042Highwire
Jan 20236210Highwire
Feb 20235835Highwire
Mar 20237321Highwire
Apr 20235132Highwire
May 20237133Highwire
Jun 20238033Highwire
Jul 202311611Highwire
Aug 20238222Highwire
Sep 20236401Highwire
Oct 20239421Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles